Screener
Climb Bio, Inc. CLYM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (44,855) | (58,751) |
| Proceeds from maturities of marketable securities | 31,900 | 16,000 |
| Net cash used in investing activities | (12,955) | (42,751) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 5 | — |
| Net cash provided by financing activities | 5 | — |
| Effect of exchange rate changes on cash and cash equivalents | — | (24) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s investing cash flow?
- Climb Bio, Inc. (CLYM) reported investing cash flow of -$12.96M in Q1 2026.
- How has Climb Bio, Inc.'s investing cash flow changed year-over-year?
- Climb Bio, Inc.'s investing cash flow increased by 69.7% year-over-year, from -$42.75M to -$12.96M.
- What is the long-term trend for Climb Bio, Inc.'s investing cash flow?
- Over 3 years (2021 to 2024), Climb Bio, Inc.'s investing cash flow has grown at a 1.7% compound annual growth rate (CAGR), from -$114.97M to -$121.09M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Climb Bio, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude